Search Results - "Monica Motwani" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

by Camidge, D. Ross, Barlesi, Fabrice, Goldman, Jonathan W., Morgensztern, Daniel, Heist, Rebecca, Vokes, Everett, Angevin, Eric, Hong, David S., Rybkin, Igor I., Barve, Minal, Bauer, Todd M., Delmonte, Angelo, Dunbar, Martin, Motwani, Monica, Parikh, Apurvasena, Noon, Elysa, Wu, Jun, Blot, Vincent, Kelly, Karen
Published in JTO clinical and research reports (01.01.2022)

Get full text

Journal Article

Development of Near Zero-Order Release Dosage Forms Using Three-Dimensional Printing (3-DP™) Technology

Development of Near Zero-Order Release Dosage Forms Using Three-Dimensional Printing (3-DP™) Technology

by Wang, Chen-Chao, Tejwani (Motwani), Monica R., Roach, Willie J., Kay, Jennifer L., Yoo, Jaedeok, Surprenant, Henry L., Monkhouse, Donald C., Pryor, Timothy J.
Published in Drug development and industrial pharmacy (01.01.2006)

Get full text

Journal Article

Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells

Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells

by SAMBOL, Elliot B, AMBROSINI, Grazia, SINGER, Samuel, GEHA, Rula C, KENNEALEY, Peter T, DECAROLIS, Penelope, O'CONNOR, Rachael, WU, Yuhsin V, MOTWANI, Monica, CHEN, Jin-Hong, SCHWARTZ, Gary K
Published in Cancer research (Chicago, Ill.) (01.06.2006)

Get full text

Journal Article

A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol

A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol

by SHAH, Manish A, KORTMANSKY, Jeremy, O'REILLY, Eileen, SALTZ, Leonard, TONG, William, KELSEN, David P, SCHWARTZ, Gary K, MOTWANI, Monica, DROBNJAK, Marija, GONEN, Mithat, YI, Sandy, WEYERBACHER, Amanda, CORDON-CARDO, Carlos, LEFKOWITZ, Robert, BRENNER, Baruch
Published in Clinical cancer research (15.05.2005)

Get full text

Journal Article

Flavopiridol Increases Sensitization to Gemcitabine in Human Gastrointestinal Cancer Cell Lines and Correlates with Down-Regulation of Ribonucleotide Reductase M2 Subunit

Flavopiridol Increases Sensitization to Gemcitabine in Human Gastrointestinal Cancer Cell Lines and Correlates with Down-Regulation of Ribonucleotide Reductase M2 Subunit

by JUNG, Christoph P, MOTWANI, Monica V, SCHWARTZ, Gary K
Published in Clinical cancer research (01.08.2001)

Get full text

Journal Article

Sequential Dependent Enhancement of Caspase Activation and Apoptosis by Flavopiridol on Paclitaxel-treated Human Gastric and Breast Cancer Cells

Sequential Dependent Enhancement of Caspase Activation and Apoptosis by Flavopiridol on Paclitaxel-treated Human Gastric and Breast Cancer Cells

by MOTWANI, M, DELOHERY, T. M, SCHWARTZ, G. K
Published in Clinical cancer research (01.07.1999)

Get full text

Journal Article

Drg1 Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes

Drg1 Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes

by SHAH, Manish A, KEMENY, Nancy, HUMMER, Amanda, DROBNJAK, Marija, MOTWANI, Monica, CORDON-CARDO, Carlos, GONEN, Mithat, SCHWARTZ, Gary K
Published in Clinical cancer research (01.05.2005)

Get full text

Journal Article

Augmentation of Apoptosis and Tumor Regression by Flavopiridol in the Presence of CPT-11 in Hct116 Colon Cancer Monolayers and Xenografts

Augmentation of Apoptosis and Tumor Regression by Flavopiridol in the Presence of CPT-11 in Hct116 Colon Cancer Monolayers and Xenografts

by MOTWANI, Monica, JUNG, Christoph, SIROTNAK, Francis M, YUHONG SHE, SHAH, Manish A, GONEN, Mithat, SCHWARTZ, Gary K
Published in Clinical cancer research (01.12.2001)

Get full text

Journal Article

Huanglian, A Chinese Herbal Extract, Inhibits Cell Growth by Suppressing the Expression of Cyclin B1 and Inhibiting CDC2 Kinase Activity in Human Cancer Cells

Huanglian, A Chinese Herbal Extract, Inhibits Cell Growth by Suppressing the Expression of Cyclin B1 and Inhibiting CDC2 Kinase Activity in Human Cancer Cells

by Li, X K, Motwani, M, Tong, W, Bornmann, W, Schwartz, G K
Published in Molecular pharmacology (01.12.2000)

Get full text

Journal Article

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates γ-Irradiation-Induced Apoptosis in Colon and Gastric Cancer Cells

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates γ-Irradiation-Induced Apoptosis in Colon and Gastric Cancer Cells

by JUNG, Christoph, MOTWANI, Monica, KORTMANSKY, Jeremy, SIROTNAK, Francis M, YUHONG SHE, GONEN, Mithat, HAIMOVITZ-FRIEDMAN, Adriana, SCHWARTZ, Gary K
Published in Clinical cancer research (01.12.2003)

Get full text

Journal Article

Lack of mannose-binding lectin-A enhances survival in a mouse model of acute septic peritonitis

Lack of mannose-binding lectin-A enhances survival in a mouse model of acute septic peritonitis

by Takahashi, Kazue, Gordon, Judith, Liu, Hong, Sastry, Kedarnath N, Epstein, Judy E, Motwani, Monica, Laursen, Inga, Thiel, Steffen, Jensenius, Jens Christian, Carroll, Michael, Ezekowitz, R.Alan B
Published in Microbes and infection (01.07.2002)

Get full text

Journal Article

Flavopiridol, a Cyclin-dependent Kinase Inhibitor, Prevents Spindle Inhibitor-induced Endoreduplication in Human Cancer Cells

Flavopiridol, a Cyclin-dependent Kinase Inhibitor, Prevents Spindle Inhibitor-induced Endoreduplication in Human Cancer Cells

by Motwani, M, Li, X, Schwartz, G K
Published in Clinical cancer research (01.03.2000)

Get full text

Journal Article

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

by Rugo, Hope S, Bardia, Aditya, Marmé, Frederik, Cortés, Javier, Schmid, Peter, Loirat, Delphine, Trédan, Olivier, Ciruelos, Eva, Dalenc, Florence, Gómez Pardo, Patricia, Jhaveri, Komal L, Delaney, Rosemary, Valdez, Theresa, Wang, Hao, Motwani, Monica, Yoon, Oh Kyu, Verret, Wendy, Tolaney, Sara M
Published in The Lancet (British edition) (21.10.2023)

Get full text

Journal Article

The in Vivo Effect of Bryostatin-1 on Paclitaxel-induced Tumor Growth, Mitotic Entry, and Blood Flow

The in Vivo Effect of Bryostatin-1 on Paclitaxel-induced Tumor Growth, Mitotic Entry, and Blood Flow

by Koutcher, J A, Motwani, M, Zakian, K L, Li, X K, Matei, C, Dyke, J P, Ballon, D, Yoo, H H, Schwartz, G K
Published in Clinical cancer research (01.04.2000)

Get full text

Journal Article

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer

by Corcoran, Ryan B, Atreya, Chloe E, Falchook, Gerald S, Kwak, Eunice L, Ryan, David P, Bendell, Johanna C, Hamid, Omid, Messersmith, Wells A, Daud, Adil, Kurzrock, Razelle, Pierobon, Mariaelena, Sun, Peng, Cunningham, Elizabeth, Little, Shonda, Orford, Keith, Motwani, Monica, Bai, Yuchen, Patel, Kiran, Venook, Alan P, Kopetz, Scott
Published in Journal of clinical oncology (01.12.2015)

Get full text

Journal Article

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer

by Camidge, D Ross, Barlesi, Fabrice, Goldman, Jonathan W, Morgensztern, Daniel, Heist, Rebecca, Vokes, Everett, Spira, Alex, Angevin, Eric, Su, Wu-Chou, Hong, David S, Strickler, John H, Motwani, Monica, Dunbar, Martin, Parikh, Apurvasena, Noon, Elysa, Blot, Vincent, Wu, Jun, Kelly, Karen
Published in Journal of clinical oncology (10.02.2023)

Get full text

Journal Article

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors

by Strickler, John H, Weekes, Colin D, Nemunaitis, John, Ramanathan, Ramesh K, Heist, Rebecca S, Morgensztern, Daniel, Angevin, Eric, Bauer, Todd M, Yue, Huibin, Motwani, Monica, Parikh, Apurvasena, Reilly, Edward B, Afar, Daniel, Naumovski, Louie, Kelly, Karen
Published in Journal of clinical oncology (20.11.2018)

Get full text

Journal Article

$A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma$

A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

by Richardson, Paul G., Polepally, Akshanth R., Motwani, Monica, Mu, Yunming, Salman, Zeena, Penugonda, Sudhir, Moreau, Philippe
Published in Blood (05.11.2020)

Get full text

Journal Article

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma

by Camidge, D Ross, Morgensztern, Daniel, Heist, Rebecca S, Barve, Minal, Vokes, Everett, Goldman, Jonathan W, Hong, David S, Bauer, Todd M, Strickler, John H, Angevin, Eric, Motwani, Monica, Parikh, Apurvasena, Sun, Zhaowen, Bach, Bruce Allen, Wu, Jun, Komarnitsky, Philip B, Kelly, Karen
Published in Clinical cancer research (01.11.2021)

Get full text

Journal Article

Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2– metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study

Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2– metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study

by Bardia, Aditya, Rugo, Hope S., Cortés, Javier, Tolaney, Sara M., Schmid, Peter, Motwani, Monica, Yoon, Oh Kyu, Boice, Jillian, Zhuo, Luting, Marmé, Frederik
Published in Journal of clinical oncology (01.06.2023)

Get full text

Journal Article

1
2
3
4
5
6
7
8
9
Next
[9]